Caelum Health

Caelum Health targeted patients with chronic digestive diseases and IBS who were seeking alternatives to pharmaceutical treatments, positioning their digital therapeutic as a personalized, software-based solution. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌The company assumed this population would embrace behavioral intervention delivered through an app rather than traditional medication. However, available sources provide limited detail about whether they successfully reached this intended audience or discovered different customer segments during their market entry. What is clear is that despite Y Combinator backing in Summer 2017, Caelum Health became inactive, suggesting their targeting assumptions or execution faced significant obstacles. The warning signs likely included challenges converting patients accustomed to conventional medical treatment into digital-first users, potential friction with healthcare providers who weren't integrated into their model, and possible difficulties demonstrating clinical efficacy at scale. The gap between building a clinically-proven treatment and achieving market adoption proved wider than anticipated, indicating their customer acquisition strategy or product-market fit assumptions did not hold.